Future Market Trends of Asthma Market Till 2021

1
Frontier Pharma Asthma- Identifying and
Commercializing First- in- Class Innovation
Published on 01 May, 2015 Number of pages
67 Single User Price 6995
While the current asthma market is almost
exclusively dominated by small molecules, which
account for approximately 99 (the exception
being Xolair), the current asthma pipeline
includes 64 biologics, accounting for 24. Small
molecules amount to 178 compounds, equating to
66.
2
Summary of the ReportAnalysis has confirmed
the asthma pipeline to be highly active, with 252
products in active development across all stages.
The range of mechanisms of action employed by
these compounds is also highly diverse,
especially in comparison to the existing market
landscape. More pertinently, the degree and
proportion of breakthrough innovations is
significant. GBI Research analysis identified 59
first-in-class programs in the asthma pipeline,
acting on 43 first-in-class molecular targets,
accounting for 23 of all products with a
disclosed molecular target and reflective of the
high degree of innovation in this indication.
This has far-reaching strategic implications for
all market participants, as, despite the high
clinical trial attrition rate, it is highly
likely that many of the first-in-class
technologies will reach the market over the
coming decade and may transform the clinical and
commercial landscape. This highlights both the
commercial and clinical appeal of developing
drugs of this class, and follows trends seen in
other therapy areas, particularly oncology.
Xolair (omalizumab), a recombinant humanized
anti-IgE monoclonal Antibody (mAb), was the first
humanized therapeutic mAb to be indicated for
asthma. It was approved by the FDA in 2003 as an
add-on therapy for adults and adolescents aged 12
and over, with moderate-to-severe allergic asthma
and symptoms not adequately controlled with
Inhaled Corticosteroids (ICS).
Click Here To Check Complete Report
3

• Scope of the Report
• The report analyzes innovation in asthma in the
  context of the overall pipeline and the current
  market landscape. In addition, it analyzes the
  deals landscape surrounding first-in-class
  products in asthma, and pinpoints opportunities
  for in-licensing. The report covers and includes
  -
• A brief introduction to asthma, including
  symptoms, pathophysiology, and an overview of
  pharmacotherapy and treatment algorithms
• The changing molecular target landscape between
  market and pipeline and particular focal points
  of innovation in the pipeline
• Comprehensive review of the pipeline for
  first-in-class therapies, analyzed by of stage of
  development, molecule type, and molecular target
• Identification and assessment of first-in-class
  molecular targets with a particular focus on
  early-stage programs of which clinical utility
  has yet to be evaluated, as well as literature
  reviews on novel molecular targets
• Assessment of the licensing and co-development
  deal landscape for asthma therapies and
  benchmarking of deals involving first-in-class
  versus non-first-in-class-products

Download Sample Brochure
4

• Reasons to buy
• The report will assist business development and
  enable marketing executives to strategize their
  product launches, by allowing them to -
• Understand the focal shifts in molecular targets
  in the asthma pipeline
• Understand the distribution of pipeline programs
  by phase of development, molecule type and
  molecular target
• Access a scientific and clinical analysis of
  first-in-class developmental programs for asthma,
  benchmarked against non-first-in-class targets
• Access a list of the first-in-class therapies
  potentially open to deal-making opportunities

Make an Inquiry Before Buying
5
Frontier Pharma Asthma- Identifying and
Commercializing First- in- Class Innovation
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
the Asthma Market are provided in the report.
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com
Click here to order a copy of Asthma Market Report